Seeking Alpha

Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment...

Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by ~30%, offering the first evidence that a medication may hamper the course of the ailment. The independent study supports LLY’s August report that showed the drug, solanezumab, slowed mental decline in those with mild Alzheimer’s.
Comments (1)
  • scubastephen
    , contributor
    Comments (20) | Send Message
    Just to be clear
    LLY claims that disease progressions were slowed
    • Using a 11-variable test: 42% in mild patients in EXP 1 cohort with pvalue = 0.008 (significant)
    • Using a 14-variable test: 20% in mild patients in EXP 2 cohort with pvalue = 0.12 (not significant)
    • Using a 14-variable test: 34% in mild patients in EXP 1+2 cohorts with pvalue = 0.001 (significant)


    The improvement in ADAS COGS was less than 2 pts, while functional improvement not statistically significant in any pool. Also, the company decided to prolong the agony by not publishing the biomarker data until 10/29 CTAD meeting in Monaco. If you're an investor listen to the call tonight and ask yourself: "Do I believe?" Because this company requires faith.
    8 Oct 2012, 03:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs